Purchase this article with an account.
Madoka Sakurai, Masayasu Kitahashi, Hirotaka Yokouchi, Takayuki Baba, Mariko Kubota-Taniai, Syuichi Yamamoto; Therapeutic Efficacy of Intravitreal Ranibizumab Combined with Reduced-Fluence Photodynamic Therapy for Polypoidal Choroidal Vasculopathy. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2062.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare the therapeutic efficacy of intravitreal ranibizumab (IVR) combined with reduced-fluence photodynamic therapy (RF-PDT) to that of IVR alone for eyes with polypoidal choroidal vasculopathy (PCV).
Fifty naïve eyes of 50 consecutive patients with PCV were studied. Nineteen eyes of 19 patients had three monthly IVR combined with RF-PDT (combined group) and 31 eyes of 31 patients had three monthly IVR alone (IVR group). Additional treatments were given when needed. The best-corrected visual acuity (BCVA) and central foveal thickness (CFT) before and after 1, 3, and 6 months were compared between the two groups. The complications were compared between the two groups.
At 6 months, the mean BCVA was significantly improved from 0.571 to 0.414 (P=0.006) in the combined group, but not significant in the IVR group (P=0.066). The CFT was significantly improved in both groups at 6 months (P<0.001), but at 1 and 3 months, there was a significant difference between two groups (P=0.012, P<0.001, respectively). Additional treatments required less frequently in the combined group during the 6 months follow-up (P=0.018); 1 patient in combined group (5.2%) and 11 patients in the IVR group (35.4%). Subretinal hemorrhage developed in 1 patient in the combined group and 2 patients in the IVR group, and vitreous hemorrhage in none of the patients in the combined group and in 1 patient in IVR group.
Combination of IVR and RF-PDT for the treatment of PCV had a significantly better early response in the CFT improvement and required fewer additional treatments than IVR alone.
This PDF is available to Subscribers Only